Equities

Prenetics Global Ltd

PRE:NMQ

Prenetics Global Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.23
  • Today's Change-0.10 / -1.88%
  • Shares traded22.54k
  • 1 Year change-55.88%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Prenetics Global Ltd is a company mainly engaged in the diagnostics and genetic testing business. The Company operates its business through two segments. The Diagnostics segment is engaged in the provision of COVID-19 testing services and operation testing laboratories. The Segment is also engaged in the development of health monitoring systems. The Prevention segment is engaged in the provision of genetics testing services to individuals and corporate entities.

  • Revenue in USD (TTM)21.74m
  • Net income in USD-54.35m
  • Incorporated--
  • Employees800.00
  • Location
    Prenetics Global Ltd7/F, K11 Atelier, 728 King's Road 000000Hong KongHKG
  • Phone+852 22109588
  • Websitehttps://ir.prenetics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nutex Health Inc247.65m-45.79m33.78m800.00--0.4991--0.1364-1.03-1.035.621.360.596761.494.09309,557.90-10.46-69.35-12.87-84.8514.0410.97-17.53-102.851.50-0.07920.7658--12.93428.2289.22------
Prenetics Global Ltd21.74m-54.35m63.83m800.00--0.3093--2.94-4.60-5.311.9416.910.07683.370.9505---19.92---24.55--40.61---259.40--2.29-5.920.0112--65.17--75.91------
CRYO-CELL International, Inc.31.37m-9.73m72.37m82.00------2.31-1.18-1.183.77-1.250.490810.314.74382,579.60-15.230.4686-21.730.709972.7970.09-31.020.81330.4495.93----3.321.41-443.57--60.30--
Oncology Institute Inc324.24m-67.88m79.52m800.00--1.39--0.2452-0.9187-0.91874.390.76911.3823.087.89405,298.80-35.28---40.88--18.3719.54-25.62-9.993.73-8.160.6036--28.4223.43-99,919.12--45.68--
Cardiff Lexington Corp12.35m-2.15m81.77m2.00------6.62-0.0102-0.01090.00070.00580.7163--1.326,173,760.00-8.97-52.27-23.24--70.0857.44-12.53-58.31--1.130.4002--21.4549.15-1,701.81------
Burning Rock Biotech Ltd (ADR)74.23m-90.29m82.86m1.14k--0.7807--1.12-0.8818-0.88180.72491.030.40911.753.57---49.76-37.09-66.95-45.2967.5970.02-121.63-123.883.09-------4.5820.8132.69------
Data as of May 03 2024. Currency figures normalised to Prenetics Global Ltd's reporting currency: US Dollar USD

Institutional shareholders

11.81%Per cent of shares held by top holders
HolderShares% Held
Eastspring Investments (Singapore) Ltd.as of 31 Dec 2023684.82k6.45%
Pacific Alliance Investment Management (HK) Ltd.as of 27 Nov 2023375.29k3.53%
Nomura Securities Co., Ltd. (Private Banking)as of 31 Dec 2023193.96k1.83%
Aspire Private Capital LLCas of 31 Mar 2024114.000.00%
BofA Securities, Inc.as of 31 Dec 2023111.000.00%
Wolverine Asset Management LLCas of 31 Dec 20231.000.00%
Millennium Management LLCas of 31 Dec 20230.000.00%
Lumyna Investments Ltd.as of 30 Sep 20220.000.00%
Geode Capital Management LLCas of 31 Dec 20230.000.00%
XTX Markets LLCas of 31 Dec 20230.000.00%
More ▼
Data from 30 Sep 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.